CIK 0001472012 · Non-accelerated filer
Immunome Inc.
Sign in to watch- Ticker
- IMNM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770694340
- Phone
- 610-321-3700
- Business address
- 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL, WA, 98011
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $334,224
- in 1 filing, $334K under 10b5-1 plans
Net −$334,224. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 56 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-10 | SWAIN SANDRA M Director | Grant or award · Director Stock Option (right to buy) | +18,864 | 18,864 | ||
| 2025-06-03 | BIENAIME JEAN JACQUES Director | Purchase | +5,000 | $9.38 | $47K | 36,415 |
| 2025-03-27 | Higgins Jack Chief Scientific Officer | Option exercise | +5,200 | $1.35 | $7K | 18,729 |
| 2025-03-27 | Higgins Jack Chief Scientific Officer | Option exercise · Employee Stock option (right to buy) | −5,200 | 173,840 | ||
| 2025-03-26 | SIEGALL CLAY B President and CEO | Purchase | +137,100 | $7.29 | $999K | 806,736 |
| 2025-03-25 | BIENAIME JEAN JACQUES Director | Purchase | +7,800 | $7.78 | $61K | 31,415 |
| 2025-03-24 | BIENAIME JEAN JACQUES Director | Purchase | +7,000 | $8.21 | $57K | 23,615 |
| 2025-03-24 | Tsai Philip Chief Technology Officer | Purchase | +12,300 | $8.42 | $104K | 33,300 |
| 2025-01-31 | SIEGALL CLAY B President and CEO | Purchase | +150,000 | $7.75 | $1.2M | 669,636 |
| 2024-11-22 | SIEGALL CLAY B President and CEO | Purchase | +33,943 | $9.78 | $332K | 519,636 |
| 2024-11-21 | SIEGALL CLAY B President and CEO | Purchase | +66,057 | $9.54 | $630K | 485,693 |
| 2024-11-21 | Lechleider Robert Chief Medical Officer | Purchase | +15,805 | $9.48 | $150K | 15,805 |
| 2024-11-21 | Tsai Philip Chief Technology Officer | Purchase | +21,000 | $9.43 | $198K | 21,000 |
| 2024-09-19 | Rosett Max Chief Financial Officer | Option exercise | +42,000 | $1.05 | $44K | 61,856 |
| 2024-09-19 | Rosett Max Chief Financial Officer | Sale | −14,380 | $16.01 | $230K | 47,476 |
| 2024-09-19 | Rosett Max Chief Financial Officer | Option exercise · Stock option (right to buy) | −42,000 | 91,848 | ||
| 2024-08-19 | Higgins Jack Chief Scientific Officer | Gift | −2,471 | 13,529 | ||
| 2024-08-16 | BIENAIME JEAN JACQUES Director | Purchase | +7,000 | $13.94 | $98K | 16,615 |
| 2024-08-15 | Higgins Jack Chief Scientific Officer | Option exercise | +19,524 | $1.35 | $26K | 19,524 |
| 2024-08-15 | Higgins Jack Chief Scientific Officer | Sale | −3,524 | $13.93 | $49K | 16,000 |
Page 6 of 8 · 159 trades